What is going on with IMV?
IMV, Inc. (IMV) stock surged today after the company announced the final topline results of its DeCidE1 Phase 2 clinical trial evaluating maveropepimut-S (MVP-S) in subjects with advanced recurrent ovarian cancer. IMV called the results "very promising,” and stated that "treatment was well-tolerated with an overall survival rate of 44.9% at 23.8 months of follow up."
IMV’s lead candidate, maveropepimut-S (formerly named DPX-Survivac), is a T cell-activating immunotherapy that combines the utility of its proprietary delivery platform (DPX) with surviving, a novel cancer target.
Shares of IMV increased 24.34% to $2.089 as of Tuesday at 10:46am.
What does this mean for IMV, Inc?
“DeCidE1” was a Phase 1b/2 multicenter, randomized, open-label study to evaluate the safety and effectiveness of MVP-S with intermittent low dose cyclophosphamide. The trial enrolled 22 subjects, and was significant as the patients had advanced platinum-sensitive and resistant ovarian cancer.
Dr Jeremy Graff, Chief Scientific Officer of IMV commented, “The translational analyses provide strong evidence that maveropepimut-S successfully elicits the generation of tumor antigen-specific T cells. Importantly, these analyses affirm the molecular and cellular mechanism of MVP-S based therapy."
This data will inform the discussion and design of a Phase 2 clinical study to be submitted to the FDA.
IMV has a Fundamental Rank of 98. Find out what this means to you and get the rest of the rankings on IMV!
IMV Inc is a clinical-stage biopharmaceutical company. The company is engaged in making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Its proprietary drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system.